ArticleMolecular genetics and genomics : MGG2026
FAM72A is associated with lung cancer proliferation and migration via the NF‑κB signaling pathway.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung cancer remains the leading cause of cancer-related deaths worldwide. While the Family with sequence similarity 72 member A (FAM72A) gene has been implicated in various cancers, its role in lung cancer is yet to be determined. This study aimed to investigate the role of FAM72A in lung cancer and the underlying mechanism. Bioinformatic analysis of The Cancer Genome Atlas-Lung Adenocarcinoma (TCGA-LUAD) dataset revealed that FAM72A was significantly upregulated in lung adenocarcinoma tissues, and high FAM72A expression was closely associated with poor patient prognosis. Western blot analysis revealed that FAM72A protein expression was significantly upregulated in multiple lung cancer cell lines (A549, H1299, and H460) compared to normal lung epithelial cells. Through a series of assays including flow cytometry, MTT, clone formation, wound healing, and Transwell experiments, we demonstrated that knockdown of FAM72A via shRNA effectively suppressed proliferation and migration in A549 and H1299 cells, while promoting apoptosis. Additionally, in vivo studies using a mouse xenograft model confirmed that FAM72A knockdown inhibited tumor growth. Mechanistic analyses showed that FAM72A knockdown is associated with inactivation of the NF‑κB signaling pathway, as knockdown led to decreased expression of p-IkBα, p-IKKα, p-NF-κB, Cyclin D1, and PCNA. In conclusion, our findings demonstrate that FAM72A contributes to lung cancer progression by regulating the activity of the NF‑κB signaling pathway, suggesting its potential as a therapeutic target for lung cancer.
Indexed as
Identifiers
42174281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.